$25 Million Gates Grant To Jump Start HIV Vaccine Research

Early this month, the International AIDS Vaccine Initiative (IAVI) announced that it had received the largest single grant ever made for AIDS research. The William A. Gates Foundation, which gave IAVI $1.5 million last June, granted IAVI $25 million over a five-year period, which the organization will use in part for work on two to three new HIV-vaccine candidates. IAVI, a New York City-based international scientific organization created to aid in bringing HIV vaccines and technology to develo

Written byMyrna Watanabe
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Early this month, the International AIDS Vaccine Initiative (IAVI) announced that it had received the largest single grant ever made for AIDS research. The William A. Gates Foundation, which gave IAVI $1.5 million last June, granted IAVI $25 million over a five-year period, which the organization will use in part for work on two to three new HIV-vaccine candidates.

IAVI, a New York City-based international scientific organization created to aid in bringing HIV vaccines and technology to developing nations and making such vaccines affordable, now can fund research on more vaccine candidates. Seth Berkley, IAVI's president, says that the funds can be put toward more studies on the vectors researchers currently have, working on the process engineering for vaccines under development, working on new vectors, and determining what genes should be in a potential vaccine.

Berkley hopes that IAVI can begin human clinical trials in Kenya with an MVA (modifed ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies